Skip Page Header

Home > The International Collaboration on ADHD and Substance Abuse (ICASA): mission, results, and future activities.

Van de Glind, Geurt and Brynte, Christoffer and Skutle, Arvid and Kaye, Sharlene and Konstenius, Maija and Levin, Frances and Mathys, Frieda and Demetrovics, Zsolt and Moggi, Franz and Ramos-Quiroga, Josep Antoni and Schellekens, Arnt and Crunelle, Cleo and Dom, Geert and van den Brink, Wim and Franck, Johan (2020) The International Collaboration on ADHD and Substance Abuse (ICASA): mission, results, and future activities. European Addiction Research , pp. 1-6. doi: 10.1159/000508870.

URL: https://www.karger.com/Article/FullText/508870

BACKGROUND: The International Collaboration on ADHD and Substance Abuse (ICASA) is a network of 28 centers from 16 countries initiated to investigate the link between attention deficit-hyperactivity disorder (ADHD) and substance use disorder (SUD). In this article, we present the mission, the results of finished studies, and the current and future research projects of ICASA.

METHODS: During the past 10 years, 3 cross-sectional studies were conducted: two International ADHD in Substance use disorders Prevalence (IASP-1 and IASP-2) studies, directed at the screening, diagnosis, and the prevalence of adult ADHD in treatment-seeking patients with SUD, and the Continuous performance test for ADHD in SUD Patients (CASP) study, testing a novel continuous performance test in SUD patients with and without adult ADHD. Recently, the prospective International Naturalistic Cohort Study of ADHD and Substance Use Disorders (INCAS) was initiated, directed at treatment provision and treatment outcome in SUD patients with adult ADHD.

RESULTS: The IASP studies have shown that approximately 1 in 6 adult treatment-seeking SUD patients also have ADHD. In addition, those SUD patients with adult ADHD compared to SUD patients without ADHD report more childhood trauma exposure, slower infant development, greater problems controlling their temperament, and lower educational attainment. Comorbid patients also reported more risk-taking behavior, and a higher rate of other psychiatric disorders compared to SUD patients without ADHD. Screening, diagnosis, and treatment of this patient group are possible even before abstinence has been achieved. The results of the CASP study are reported separately in this special issue.

CONCLUSIONS: The ICASA research to date has demonstrated a high prevalence of comorbid ADHD and SUD, associated with elevated rates of additional comorbidities and risk factors for adverse outcomes. More research is needed to find the best way to treat these patients, which is the main topic of the ongoing INCAS study.


Item Type
Article
Publication Type
International, Review
Drug Type
All substances
Intervention Type
General / Comprehensive
Date
29 June 2020
Identification #
doi: 10.1159/000508870
Page Range
pp. 1-6
Publisher
Karger
EndNote

Repository Staff Only: item control page